Theriva Biologics Inc. (TOVX) Tuesday announced positive data from the Phase 1 trial evaluating the safety and tolerability of two intravitreal injections of its investigational oncolytic adenovirus VCN-01 in patients with intraocular retinoblastoma that is refractory to chemotherapy or radiotherapy.
The trial was an investigator sponsored one.
Steven Shallcross, chief executive officer of Theriva Biologics said, "We look forward to building on the encouraging safety profile and antitumor activity, which further supports and informs the design of our proposed Phase 2 clinical trial."
Retinoblastoma is a tumor that originates in the retina and is the most common type of eye cancer in children. VCN-01 is a systemically administered oncolytic adenovirus designed to selectively and aggressively replicate within tumor cells and degrade the tumor stroma.
Shares of Theriva is currently at $0.41, up $4.622 on a volume of 46,927.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.